Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Passes Above 200-Day Moving Average – Here’s Why

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $136.25 and traded as high as $175.80. Jazz Pharmaceuticals shares last traded at $174.39, with a volume of 1,348,455 shares changing hands.

Analyst Ratings Changes

JAZZ has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price objective on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. JPMorgan Chase & Co. cut their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. UBS Group reissued a “neutral” rating and issued a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $200.47.

Jazz Pharmaceuticals Price Performance

The company has a 50-day moving average of $161.64 and a 200-day moving average of $136.25. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The stock has a market cap of $10.60 billion, a price-to-earnings ratio of -28.73, a PEG ratio of 0.81 and a beta of 0.27.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president directly owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rick E. Winningham sold 5,500 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the transaction, the director directly owned 8,893 shares in the company, valued at $1,608,387.98. This represents a 38.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 123,791 shares of company stock valued at $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $40,000. Quent Capital LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter worth about $44,000. Finally, Geneos Wealth Management Inc. grew its position in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.